{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:22:41Z","timestamp":1781536961444,"version":"3.54.5"},"reference-count":120,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>This review systematically examines the oral complications associated with conventional and novel anti-cancer therapies. It highlights that while molecularly targeted agents including monoclonal antibodies targeting the vascular endothelial growth factor and its receptor, the epidermal growth factor receptor, tyrosine kinase inhibitors, and immune checkpoint inhibitors tend to exhibit a lower overall toxicity profile compared to traditional cytotoxic chemotherapeutics, they are nonetheless linked to significant oral adverse events. These complications encompass inflammatory mucosal reactions known as mucositis, salivary gland dysfunction leading to a sensation of dryness in the mouth, taste alterations referred to as dysgeusia, and, critically, medication-related osteonecrosis of the jaw. In particular, bone-modifying agents such as bisphosphonates and denosumab disrupt bone remodeling and the formation of new blood vessels, thereby increasing the susceptibility to osteonecrosis of the jaw, especially following invasive dental procedures. The review delineates the multifactorial pathogenesis underlying these toxicities, which involves direct cell toxicity, impaired wound healing, and secondary infections. Furthermore, it emphasizes the importance of pre-treatment dental evaluation and preventive strategies including patient education, prophylactic dental care, and the integration of adjunctive therapies such as laser therapy and autologous platelet concentrates to mitigate these adverse effects. The analysis advocates for interdisciplinary collaboration between oncologists and dental professionals to optimize management protocols, enhance treatment adherence, and ultimately improve the quality of life for oncology patients undergoing anti-cancer therapy.<\/jats:p>","DOI":"10.3390\/cancers17071061","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T11:06:48Z","timestamp":1742555208000},"page":"1061","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Navigating Stomatologic Complications Secondary to Antineoplastic Agents\u2014A Comprehensive Review"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7948-3362","authenticated-orcid":false,"given":"Ion Alexandru","family":"Popovici","sequence":"first","affiliation":[{"name":"Department of Implant Prosthetic Therapy, Faculty of Dentistry, University of Medicine and Pharmacy \u201cCarol Davila\u201d Bucharest, 010221 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia Anca","family":"Kajanto","sequence":"additional","affiliation":[{"name":"Institute of Oncology \u201cAlexandru Trestioreanu\u201d, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Roxana","family":"Popovici","sequence":"additional","affiliation":[{"name":"Institute of Oncology \u201cAlexandru Trestioreanu\u201d, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9246-9441","authenticated-orcid":false,"given":"Iolanda Georgiana","family":"Augustin","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy, 94800 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0414-1607","authenticated-orcid":false,"given":"Laurentia Nicoleta","family":"Gales","sequence":"additional","affiliation":[{"name":"Institute of Oncology \u201cAlexandru Trestioreanu\u201d, 022328 Bucharest, Romania"},{"name":"Oncology Department, University of Medicine and Pharmacy \u201cCarol Davila\u201d Bucharest, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-009-0984-y","article-title":"Matrix metalloproteinases: Key regulators in the pathogenesis of chemotherapy-induced mucositis?","volume":"64","author":"Gibson","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor","year":"2010","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(04)01467-6","article-title":"Monoclonal antibodies as therapeutic agents for cancer","volume":"5","author":"Harris","year":"2004","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11523-010-0149-2","article-title":"Perspectives in drug development for metastatic renal cell cancer","volume":"5","author":"Basu","year":"2010","journal-title":"Target. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/jjco\/hyq037","article-title":"Targeted therapy in breast cancer: Current status and future directions","volume":"40","author":"Mukai","year":"2010","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/cncr.10372","article-title":"Monoclonal antibodies to target epidermal growth factor receptor\u2013positive tumors","volume":"94","author":"Herbst","year":"2002","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semcancer.2003.11.006","article-title":"Targeted therapies in myeloid leukemia","volume":"14","author":"John","year":"2004","journal-title":"Semin. Cancer Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.oraloncology.2011.03.028","article-title":"Oral complications of targeted cancer therapies: A narrative literature review","volume":"47","author":"Watters","year":"2011","journal-title":"Oral. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2174\/138161210791034003","article-title":"Bisphosphonates as treatment of bone metastases","volume":"16","author":"Holen","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.biomaterials.2003.11.024","article-title":"Osteoblast proliferation and maturation by bisphosphonates","volume":"25","author":"Im","year":"2004","journal-title":"Biomaterials"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis","volume":"44","author":"Cremers","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_15","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1056\/NEJMcpc0800341","article-title":"Case 9\u20132008\u2014A 65-year-old woman with a nonhealing ulcer of the jaw","volume":"358","author":"Dodson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: Bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1634\/theoncologist.2009-0115","article-title":"Bisphosphonates and time to osteonecrosis development","volume":"14","author":"Palaska","year":"2009","journal-title":"Oncologist"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/j.oooo.2012.01.046","article-title":"Review of current literature and implications of RANKL inhibitors for oral health care providers","volume":"116","author":"Epstein","year":"2013","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00198-010-1177-6","article-title":"Denosumab-related osteonecrosis of the jaws","volume":"22","author":"Kyrgidis","year":"2011","journal-title":"Osteoporos. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2174\/156800909789760393","article-title":"Challenging the current approaches to multiple myeloma-related bone disease: From BPs to target therapy","volume":"9","author":"Tassone","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_22","unstructured":"Amgen (2010). Highlights of Prescribing Information. Xgeva (Deno-Sumab) Injection, for Subcutaneous Use, Amgen."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2174\/156800909789760375","article-title":"Denosumab: The era of targeted therapies in bone metastatic diseases","volume":"9","author":"Santini","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice Guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Temin","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s40496-015-0069-4","article-title":"Oral mucositis induced by anticancer therapies","volume":"2","author":"Zecha","year":"2015","journal-title":"Curr. Oral. Health Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00520-010-0873-2","article-title":"A systematic review on patients undergoing cancer therapy","volume":"18","author":"Hong","year":"2010","journal-title":"Support. Care Cancer"},{"key":"ref_27","unstructured":"National Cancer Institute (2025, February 05). Oral Complications of Chemotherapy and Head\/Neck Radiation (PDQ\u00ae) Health Professional Version, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK65881.5\/?report=printable."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.4317\/medoral.23191","article-title":"Review and update on drugs related to the development of osteonecrosis of the jaw","volume":"25","author":"Eguia","year":"2020","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-010-0933-9","article-title":"Osteonecrosis of the jaw and bevacizumab therapy","volume":"122","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105543","DOI":"10.1016\/j.oraloncology.2021.105543","article-title":"Oral mucosal pseudotumor\u2014Novelty complication in a patient undergoing bevacizumab therapy","volume":"122","author":"Kudva","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40729-019-0188-0","article-title":"A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants","volume":"5","author":"Maluf","year":"2019","journal-title":"Int. J. Implant. Dent."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","article-title":"Osteonecrosis of the mandible associated with bevacizumab therapy","volume":"115","author":"Rosa","year":"2013","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.arbres.2012.01.007","article-title":"Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab","volume":"48","author":"Katsenos","year":"2012","journal-title":"Arch. Bronconeumol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105660","DOI":"10.1016\/j.oraloncology.2021.105660","article-title":"Ramucirumab-related osteonecrosis of the jaw","volume":"125","author":"Singh","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000512036","article-title":"Panitumumab-induced paronychia: A case report and a brief review of the literature","volume":"7","author":"Yorulmaz","year":"2021","journal-title":"Skin. Appendage Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40120-024-00616-7","article-title":"Dental Adverse Effects of Anti-CD20 Therapies","volume":"13","author":"Bartak","year":"2024","journal-title":"Neurol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00520-014-2434-6","article-title":"Oral health in oncology: Impact of immunotherapy","volume":"23","author":"Jackson","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.oooo.2022.09.020","article-title":"Complications After Dental Extractions In Patients Taking Biologic Agents","volume":"135","author":"Davila","year":"2023","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tripleo.2011.08.024","article-title":"Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications","volume":"113","author":"Migkou","year":"2012","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.4317\/jced.58323","article-title":"Photobiomodulation laser therapy in a Lenvatinib-related osteonecrosis of the jaw: A case report","volume":"13","author":"Monteiro","year":"2021","journal-title":"J. Clin. Exp. Dent."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/adj.12254","article-title":"Osteonecrosis of the jaw in a patient receiving cabozantinib","volume":"60","author":"Marino","year":"2015","journal-title":"Aust. Dent. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"omad146","DOI":"10.1093\/omcr\/omad146","article-title":"Pazopanib-induced trismus in a young male with metastatic renal cell carcinoma: A case report and literature review","volume":"2024","author":"Benhima","year":"2024","journal-title":"Oxford Med. Case Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-017-3903-5","article-title":"Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and VEGFR tyrosine kinase inhibitors","volume":"26","author":"Loyson","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.adaj.2022.03.009","article-title":"Effect of imatinib on oral wound healing after extraction: A rare case report","volume":"153","author":"Myers","year":"2022","journal-title":"J. Am. Dent. Assoc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100228","DOI":"10.1016\/j.oor.2024.100228","article-title":"Ibrutinib-associated osteonecrosis of the jaw","volume":"9","author":"Singh","year":"2024","journal-title":"Oral Oncol. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bjoms.2019.05.017","article-title":"Everolimus-induced osteonecrosis of the jaw in the absence of bisphosphonates: A case report","volume":"57","author":"Akkach","year":"2019","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/odi.12795","article-title":"Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients","volume":"24","author":"Arena","year":"2018","journal-title":"Oral Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1634\/theoncologist.2009-0155","article-title":"Safety of bevacizumab in patients with advanced cancer: A meta-analysis of randomized controlled trials","volume":"15","author":"Stollenwerk","year":"2010","journal-title":"Oncologist"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1517\/14740338.2015.1074677","article-title":"Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: A systematic review and meta-analysis","volume":"14","author":"ElHalawani","year":"2015","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/annonc\/mdm399","article-title":"An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy","volume":"19","author":"Siena","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.24120","article-title":"Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy","volume":"115","author":"Tejwani","year":"2009","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.radonc.2008.09.018","article-title":"Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer","volume":"90","author":"Pryor","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: Panitumumab (Vectibix\u2122)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncologist"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Elad, S., Yarom, N., and Zadik, Y. (2023). Immunotherapy-related oral adverse effects: Immediate sequelae, chronicity and secondary cancer. Cancers, 15.","DOI":"10.3390\/cancers15194781"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.5301\/tj.5000405","article-title":"Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: Attention to Oral District","volume":"102","author":"Ponzetti","year":"2016","journal-title":"Tumori"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bjoms.2016.11.315","article-title":"Medication-related osteonecrosis of the jaw associated with aflibercept","volume":"55","author":"Zarringhalam","year":"2017","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.4317\/medoral.22858","article-title":"Osteonecrosis of the jaws produced by sunitinib: A systematic review","volume":"24","author":"Vallina","year":"2019","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Villa, A., and Kuten-Shorrer, M. (2023). Pathogenesis of oral toxicities associated with targeted therapy and immunotherapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098188"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Papadopoulou, E., Vardas, E., Tziveleka, S., Georgaki, M., Kouri, M., Katoumas, K., Piperi, E., and Nikitakis, N.G. (2022). Oral side effects in patients with metastatic renal cell carcinoma receiving the antiangiogenic agent pazopanib\u2014Report of three cases. Dent. J., 10.","DOI":"10.3390\/dj10120232"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Wang, F., Wei, S., Zhang, Z., Zhang, Y., He, J., and Sun, B. (2022). Osimertinib: Another medication related to osteonecrosis of the jaws? A case report and literature review. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.947947"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/ijc.32399","article-title":"Osimertinib and jaw osteonecrosis? A case report","volume":"145","author":"Subramanian","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00520-014-2228-x","article-title":"Appropriate and necessary oral care for people with cancer: Guidance to obtain the right oral and dental care at the right time","volume":"22","author":"Epstein","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_67","first-page":"178","article-title":"Dental management of the complications of radio and chemotherapy in oral cancer","volume":"8","year":"2003","journal-title":"Med. Oral"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"135","DOI":"10.12968\/denu.2012.39.2.135","article-title":"Oral and dental management for head and neck cancer patients treated by chemotherapy and radiotherapy","volume":"39","author":"McCaul","year":"2012","journal-title":"Dent. Update"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jop.12549","article-title":"Efficacy of chlorhexidine for the prevention and treatment of oral mucositis in cancer patients: A systematic review with meta-analyses","volume":"46","author":"Cardona","year":"2017","journal-title":"J. Oral Pathol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"560","DOI":"10.12968\/denu.2010.37.8.555","article-title":"Current practice in dental oncology in the UK","volume":"37","author":"Barclay","year":"2010","journal-title":"Dent. Update"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11912-024-01518-5","article-title":"Oral Complications and Management Strategies for Cancer Patients: Principles of Supportive Oncology in Dentistry","volume":"26","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00520-010-0827-8","article-title":"A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Prevalence, severity and impact on quality of life","volume":"18","author":"Jensen","year":"2010","journal-title":"Support. Care Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41415-022-5197-3","article-title":"Oral prehabilitation for patients with head and neck cancer: Getting it right\u2014The Restorative Dentistry-UK consensus on a multidisciplinary approach","volume":"233","author":"McCaul","year":"2022","journal-title":"Br. Dent. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1590\/1981-863720140004000007573","article-title":"Oral complications in patients receiving head and neck radiation therapy: A literature review","volume":"62","author":"Sari","year":"2014","journal-title":"RGO\u2014Rev. Ga\u00facha Odontol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws\u20142022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/odi.13160","article-title":"Workshop of European task force on medication-related osteonecrosis of the jaw\u2014Current challenges","volume":"25","author":"Schiodt","year":"2019","journal-title":"Oral Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/dj11010023","article-title":"Osteonecrosis of the Jaw","volume":"11","year":"2023","journal-title":"Dent. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.morpho.2020.11.008","article-title":"Medication-related osteonecrosis and osteoradionecrosis of the jaws: Update and current management","volume":"105","author":"Fauvel","year":"2021","journal-title":"Morphologie"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Yong, C.W., Robinson, A., and Hong, C. (2022). Dental Evaluation Prior to Cancer Therapy. Front. Oral Health, 3.","DOI":"10.3389\/froh.2022.876941"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Inchingolo, A.M., Malcangi, G., Ferrara, I., Patano, A., Viapiano, F., Netti, A., Azzollini, D., Ciocia, A.M., de Ruvo, E., and Campanelli, M. (2023). MRONJ Treatment Strategies: A Systematic Review and Two Case Reports. Appl. Sci., 13.","DOI":"10.3390\/app13074370"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Scribante, A., Ghizzoni, M., Pellegrini, M., Pulicari, F., and Spadari, F. (2023). Laser Devices and Autologous Platelet Concentrates in Prevention and Treatment of MRONJ: A Systematic Review. Medicina, 59.","DOI":"10.3390\/medicina59050972"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1529-8019.2010.01322.x","article-title":"Lichen planus and lichenoid reactions of the oral mucosa","volume":"23","author":"Schlosser","year":"2010","journal-title":"Dermatol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.2014-0169","article-title":"Lichenoid mucosal reaction to rituximab","volume":"19","author":"Hochberg","year":"2014","journal-title":"Oncologist"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0781.2011.00621.x","article-title":"Photoinduced dermatitis and oral lichenoid reaction in a CML patient treated with imatinib mesylate","volume":"28","author":"Brazzelli","year":"2012","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0714.2006.00406.x","article-title":"The role of histopathological characteristics in distinguishing amalgam-associated oral lichenoid reactions and oral lichen planus","volume":"35","author":"Thornhill","year":"2006","journal-title":"J. Oral Pathol. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.det.2020.05.012","article-title":"Adverse drug events in the oral cavity","volume":"38","author":"Yuan","year":"2020","journal-title":"Dermatol. Clin."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in CML patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.oooo.2020.10.015","article-title":"The blue palate\u2014A case series of imatinib-related oral pigmentation and literature review","volume":"131","author":"Donnell","year":"2021","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-3083.2008.02706.x","article-title":"Imatinib-associated hyperpigmentation, a side effect that should be recognized","volume":"23","author":"McPherson","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1007\/s00784-019-02886-0","article-title":"Association of oral mucosa hyperpigmentation with imatinib mesylate use: A cross-sectional study and systematic literature review","volume":"23","author":"Oliveira","year":"2019","journal-title":"Clin. Oral. Investig."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/ors.12194","article-title":"Intraoral hyperpigmentation due to imatinib mesylate","volume":"9","author":"Pancholi","year":"2016","journal-title":"Oral Surg."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D3472203P2","article-title":"Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST","volume":"14","author":"Alexandrescu","year":"2008","journal-title":"Dermatol. Online J."},{"key":"ref_93","first-page":"223","article-title":"Chemotherapy-associated tongue hyperpigmentation and blue lunula","volume":"12","author":"Casamiquela","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"21047","DOI":"10.3402\/jchimp.v3i3-4.21047","article-title":"Tongue hyperpigmentation associated with chemotherapy","volume":"3","author":"Alfreijat","year":"2013","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with mTOR inhibitors in cancer patients","volume":"116","author":"Sonis","year":"2010","journal-title":"Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","article-title":"A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients","volume":"49","author":"Martins","year":"2013","journal-title":"Oral Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: Mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cncr.33436","article-title":"Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Seidel, J.A., Otsuka, A., and Kabashima, K. (2018). Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00086"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tripleo.2005.12.016","article-title":"Relationship between mucositis and changes in oral microflora during cancer chemotherapy","volume":"103","author":"Brennan","year":"2007","journal-title":"Oral Surg. Oral Pathol. Oral Radiol. Endodontol."},{"key":"ref_104","first-page":"e201","article-title":"Treatment of oral mucositis due to chemotherapy","volume":"8","year":"2016","journal-title":"J. Clin. Exp. Dent."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2354.2006.00684.x","article-title":"The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: A systematic review","volume":"15","author":"Potting","year":"2006","journal-title":"Eur. J. Cancer Care"},{"key":"ref_106","first-page":"e31","article-title":"Dental treatment considerations in the chemotherapy patient","volume":"3","year":"2011","journal-title":"J. Clin. Exp. Dent."},{"key":"ref_107","first-page":"CD000978","article-title":"Interventions for preventing oral mucositis in cancer patients with cancer receiving treatment","volume":"13","author":"Worthington","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/cncr.28592","article-title":"MASCC\/ISOO clinical practice guidelines for management of mucositis secondary to cancer therapy","volume":"120","author":"Lalla","year":"2014","journal-title":"Cancer"},{"key":"ref_109","first-page":"413","article-title":"Evaluation of zinc sulfate in prevention of chemotherapy-induced mucositis: A double-blind RCT","volume":"15","author":"Deghatipour","year":"2012","journal-title":"Arch. Iran. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"v139","DOI":"10.1093\/annonc\/mdv202","article-title":"Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines","volume":"26","author":"Peterson","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_111","first-page":"615","article-title":"Burning mouth syndrome","volume":"65","author":"Grushka","year":"2002","journal-title":"Am. Fam. Physician"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Mistretta, C.M., and Kumari, A. (2019). Hedgehog Signaling Regulates Taste Organs and Oral Sensation: Distinctive Roles in the Epithelium, Stroma, and Innervation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061341"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1152\/jn.00822.2014","article-title":"Hedgehog pathway blockade with LDE225 disrupts taste organs and sensation","volume":"113","author":"Kumari","year":"2015","journal-title":"J. Neurophysiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in advanced basal cell carcinoma: Primary analysis of STEVIE trial","volume":"86","author":"Hauschild","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Imai, H., Soeda, H., Komine, K., Otsuka, K., and Shibata, H. (2013). Preliminary estimation of chemotherapy-induced dysgeusia in Japanese cancer patients. BMC Palliat. Care, 12, (In Japanese).","DOI":"10.1186\/1472-684X-12-38"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/jdv.16230","article-title":"Sonidegib and vismodegib in locally advanced basal cell carcinoma: A joint expert opinion","volume":"34","author":"Dummer","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2015.01.018","article-title":"Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive NSCLC","volume":"88","author":"Koizumi","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e227722","DOI":"10.1001\/jamanetworkopen.2022.7722","article-title":"Association of immune checkpoint inhibitors with neurologic adverse events: A systematic review and meta-analysis","volume":"5","author":"Farooq","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Albarran, V., Chamorro, J., Rosero, D.I., Saavedra, C., Soria, A., Carrato, A., and Gajate, P. (2022). Neurologic toxicity of immune checkpoint inhibitors: A review. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.774170"},{"key":"ref_120","first-page":"77","article-title":"Influence of parenteral chemotherapy on oral mucosa health","volume":"19","author":"Rahnama","year":"2015","journal-title":"Contemp. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1061\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:58:06Z","timestamp":1760029086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":120,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071061"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071061","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]}}}